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The Centers for Disease Control and Prevention suggests the challenge test for children whose
bloodlead levels are 1.21-2.12 pmol/L (2544pg/dL). However, thechallenge testisdifficultto
perform. By identifying children who are likely to have a negative challenge test, a medical
provider can minimize the number ofchildren undergoing this test. The goal ofthis studywas
to identify common tests that are likely to predict the outcome ofthe challenge test. Itwas con-
ducted as a clinical descriptive study from a series ofpatients who underwent a CaNa2EDTA
challenge test. Results from 178 challenge tests were eligible for analysis. The mean age ofchil-
dren undergoing the challenge test was 38.2 months, and the mean blood lead level was 1.83
pmol/L (38 pg/dL). Blood lead level, age, erythrocyte protoporphyrin level, and RATE (a mea-
sure ofthe rate ofchange ofthe blood leadlevel) wereeither not sensitive or notspecific in pre-
dicting the outcome of a challenge test. However, based on a logistic regression model using
blood lead level, age, and RATE, we determined criteria that would have identified all children
whowouldhavehadapositive challenge testwhile excluding mostchildrenwhowouldhave bad
a negative challenge test. Based on this model, we recommend that the challenge test be con-
ducted on children . 36 months ofage who have a blood lead level between 1.45 and 1.64
pmol/L (30-34 pgldL) and on children who have a blood lead level 1.69-2.12 pmol/L (35-44
pgldL) regardless ofage. This approach would have.tested all children who subsequentlywould
have had apositive challenge testwhile testingonly39% ofchildren whowouldhavehadaneg-
ative challenge test. Key words. calcium disodium edetate, challenge test, chelation, lead toxicity.
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The Centers for Disease Control and
Prevention (CDC) recommends that the
calcium disodium edetate (CaNa2EDTA)
challenge test be considered for children
who have blood lead levels of 1.21-2.12
pmol/L (25-44 pg/dL) to determine
whether chelation is indicated (1). This rec-
ommendation is based on a past study
(2,3). However, the challenge test is a
potentially difficult procedure because of
the required 8-hr urine collection, often on
an active toddler. By identifying children
who are likely to have a negative challenge
test, a medical provider can minimize the
number of children undergoing this test.
The objective of this study was to identify
factors likely to predict the outcome of
challenge tests.
Materials and Methods
The Finger Lakes Lead Poisoning Prevention
and Treatment Center at Rochester General
Hospital (Rochester, NY) offers medical
services to children who have elevated blood
lead levels in a nine-county area surround-
ing Rochester, New York. Children can be
referred to this center by their physicians for
a challenge test with CaNa2EDTA if their
blood lead levels are 1.21-2.12 pmol/L
(25-44 pg/dL). Parents of all children
admitted to Rochester General Hospital sign
a consent form on admission; the form
allows staff physicians to review the chart
and abstract data for research purposes.
We obtained a venous lead level, ery-
throcyte protoporphyrin (EP) level, serum
iron, total iron binding capacity (TIBC),
and hematocrit immediately before admin-
istering CaNa2EDTA. We administered
CaNa2EDTA at a dose of500 mg/mi2 either
intravenously over 1 hr or intramuscularly
mixed 3:1 by volume with 2% lidocaine;
the result ofa challenge test is unaffected by
whether the CaNa2EDTA is administered
intramuscularly or intravenously (4).
Subsequently, an 8-hr urine sample was col-
lected and stored in an acid-washed, lead-
free plastic container. Maintenance oral
fluid intake was encouraged throughout the
urine collection; if oral intake fell below
maintenance in any 2-hr period during the
8-hr collection, we administered intra-
venous fluids at a maintenance rate.
Blood and urine lead levels were mea-
sured by graphite furnace atomic absorp-
tion spectrometry (5). Blood samples were
assayed twice, and the mean was reported.
The laboratory participates in a proficiency
testing program for the blood lead assay.
There is no proficiency testing program for
the determination oflead in urine; howev-
er, quality control is conducted on urine
samples acquired from the New York State
Department of Health (Albany, NY).
During 1997 and 1998, 62 quality control
samples were assayed, and the values of all
were within two standard deviations of the
mean (6). The EP level was assayed fluori-
metrically (74. Serum iron was measured
using Ferrozine (Hach Chemical Co.,
Ames, IA) to form a colored complex with
reduced iron (8). TIBC was measured using
Ferrozine (9).
The results ofa challenge test were eligi-
ble for analysis if there were no losses of
urine during the 8-hr urine collection. We
compared the mean age and blood lead
level at the time of referral among the
excluded challenge tests and the eligible
challenge tests to assess whether the two
groups were comparable.
The proportions of positive challenge
tests were determined for different strata of
blood lead levels for all eligible children
having challenge tests and for those whose
EP level was . 0.62 pmol/L (> 35 pg/dL).
To identify variables predictive ofa positive
challenge test [i.e., urine lead:CaNa2EDTA
ratio . 0.60 (1)] that we could introduce
into multivariate analysis, we calculated
Pearson correlation coefficients between the
urine lead:CaNa2EDTA ratio and blood
lead level at the time of referral, blood lead
level on the day of the challenge test, age,
hematocrit, iron saturation (i.e., serum
iron/TIBC), EP level, and RATE (i.e., the
blood lead level on the day ofthe challenge
test minus the blood lead level at the time
of referral, divided by the number of days
between the two blood lead level measure-
ments. RATE is a measure of the rate of
change of the blood lead level; a positive
RATE indicates the blood lead level rose
between the time ofreferral and the challenge
test. We defined significant comparisons (i.e.,
Pearson correlation coefficient with ap-value
< 0.10) as explanatory variables, and used
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these in multivariate analysis. We also con-
ducted bivariate analysis on these explanatory
variables to assess whether each individually
would predict the outcome of a challenge
test (i.e., positive versus negative); sensitivity,
specificity, positive predictive value, and neg-
ative predictive value were calculated.
We conducted multivariate analysis
using logistic regression. We devised two
models ofa child diagnosed with a moder-
ately elevated blood lead level [1.21-2.12
pmol/L (25-44 pg/dL)]. In the first model
a medical provider determines the likeli-
hood of a positive challenge test conducted
within 2 weeks ofthe diagnosis; in the sec-
ond model, a medical provider obtains a
second blood lead level and EP level 2-4
weeks after the diagnosis and then deter-
mines the likelihood ofa positive challenge
test. In the first model we used referral
blood lead level and age as independent
variables among the challenge tests con-
ducted within 2 weeks ofthe referral; in the
second model we used blood lead level at
the time ofthe challenge test, age, EP level,
and RATE as independent variables among
the challenge tests conducted 2-4 weeks
after the referral. The aforementioned inde-
pendent variables were all significantly cor-
related to the urine lead:CaNa2EDTA ratio
(Table 1). Both blood lead level measures
were coded into 0.24 1mol/L (5 pg/dL)
strata [i.e., 1.21-1.40 1mol/L (25-29
pg/dL), 1.44-1.64 1mol/L (30-34 pg/dL),
etc.]. Age was dichotomized into < 36
months and . 36 months strata. EP level
was dichotomized into < 0.62 jmol/L (< 35
pg/dL) and .0.62 jig/dL (2 35 pg/dL) stra-
ta. RATE was dichotomized into < 0
ggldL/day and 2 0 pg/dL/day strata. We
introduced all combinations of the respec-
tive variables for each of the two models
into forced-entry logistic regression using
SPSS software (SPSS, Inc., version 4.0,
Chicago, IL). Our objective was to find the
model and set ofindependent variables that
would correctly classify all true-positive
challenge tests (i.e., 100% sensitivity) while
minimizing the number of true-negative
challenge tests thatwere falsely classified.
Results
A total of 217 children were referred
between January 1992 and September 1998
for 253 challenge tests (mean 1.2 challenge
tests per child; range 1-5). Among these
children, 51% were male; 68% were
African American, 14% were Hispanic,
16% were white, and 2% were an unde-
fined race. The mean age at the time ofthe
challenge test was 37.7 months, and the
mean blood lead level at the time ofreferral
was 1.83 pmol/L (38 pg/dL); all blood lead
levels were assayed on venous blood.
A total of 75 challenge tests had urine
losses during the 8-hr collection period, leav-
ing 178 that were eligible for analysis. These
eligible challenge tests were made up ofchil-
dren with a mean age of38.2 months, and a
mean blood lead level at the time ofreferral
of 1.83 pmol/L (38 pg/dL). The meanvalues
of these two variables were not significantly
different from the respective mean values of
the sample ofexcluded challenge tests. There
was a mean of 16 days (range 3-78 days)
between the blood lead level at the time of
referral and the challenge test; 89 (50%)
challenge tests were conducted within 14
days of the referral blood lead level, and 73
(41%) were conducted 15-31 days after the
referral blood lead level. Although nearly all
children had a blood lead level between 1.21
and 2.12 1mol/L (25-44 pg/dL) at the time
of referral [two children who each had a
referral blood lead level of2.27 1imol/L (47
pg/dL) were challenged at the request of a
parent], by the dayofthe challenge test some
children had a blood lead level outside this
range. The mean value of blood and urine
tests among the eligible challenge tests are
reported in Table 2.
Among the eligible 178 challenge tests,
40 (22%) were positive and 138 were nega-
tive. Table 3 lists the proportion of chal-
lenge tests that were positive at different
strata ofblood lead levels among the eligible
challenge tests. There were no positive chal-
lenge tests among children with a blood
lead level < 1.40 pmol/L (< 29 pg/dL),
whereas 71% of the challenge tests were
positive among children with a blood lead
level 2.41-2.61 jmol/L (50-54 pg/dL).
Restricting the sample to children with EP
levels . 0.62 jmol/L (. 35 pg/dL) resulted
in higher proportions of positive challenge
tests for nearly every stratum of blood lead
level (Table 2).
Table 1 lists the Pearson correlation
coefficients between several factors and the
urine lead:CaNa2EDTA ratio. Blood lead
level at the time ofreferral, blood lead level
Table 1. Pearson correlation coefficient between
variables and urine lead:CaNa2EDTA ratio.
Variable Correlation n p-Value
Referral leada 0.37 178 < 0.01
Challenge leadb 0.59 174 < 0.01
Age 0.22 178 <0.01
Hematocrit -0.01 161 0.85
Iron saturationc 0.11 168 0.16
Erythrocyte 0.30 150 <0.01
protoporphyrin
RATEd 0.39 174 <0.01
'Blood lead level atthe time of referral. bBlood lead level
obtained on the day of the challenge test. cSerum
iron/total iron binding capacity. dDefined as the blood
lead level on the day of the challenge test minus the
blood lead level at the time of referral, divided by the
number of days between the two lead levels.
on the day of the challenge test, age, EP
level, and RATE were significandy correlat-
ed to the urine lead:CaNa2EDTA ratio
(i.e., p < 0.10), and were defined as
explanatoryvariables. Table 4 lists the sensi-
tivity, specificity, positive predictive value,
and negative predictive value among the lat-
ter explanatory variables. Although the cor-
relation coefficient did not define iron satu-
ration as an explanatory variable, we never-
theless conducted bivariate analysis on it
because a past study found that it predicted
the outcome ofa challenge test (10).
In bivariate analysis, we found age to
only be a fair predictor ofthe outcome ofa
challenge test. Among challenge tests con-
ducted at age < 36 months, 15% were posi-
tive, while among challenge tests conduct-
ed at age > 36 months, 31% were positive.
However, age at this cutofflacks both sen-
sitivity and specificity in predicting the
outcome ofa challenge test (Table 4).
Among the 178 challenge tests, 150
were accompanied by an EP level; this sub-
sample of challenge tests is comparable to
the eligible challenge tests with regard to age
and all variables listed in Table 2. A low EP
level is an excellent predictor of a negative
challenge test. Three percent of challenge
tests with an EP level < 0.62 pmol/L (< 35
pg/dL) were positive, and 31% ofchallenge
tests with an EP level 2 0.62 .mol/L (. 35
pg/dL) were positive. Blood lead level was
comparable between these two strata of EP
level. The mean blood lead level on the day
of chelation among children with EP levels
< 0.62 1imol/L (< 35 gg/dL) and EP level .
0.62 1mol/L (> 35 gg/dL) was 1.49 p.mol/L
[31 pg/dL; range 0.72-2.32 pmol/L (15-48
1pg/dL)] and 1.74 1mol/L [36 pg/dL; range
0.58-2.61 pmol/L (12-54 ,ug/dL)], respec-
tively. The EP level is very sensitive; 97% of
positive challenge tests had an EP level
> 0.62 1mol/L (> 35 1gIdL). However, this
Table 2. Mean value of blood and urine tests
among the eligible challenge tests (n= 178).
Variable Mean Range
Referral lead (pg/dL)a 38 31-47
Challenge lead(pg/dL)b 34 12-54
Hematocrit (%) 36 27-44
Iron saturation (%)c 18 2-52
Erythrocyte protoporphyrin 76 7-425
(pg/dL)d
Urine lead concentration 394 20-5,600
(pg/L)
Lead excreted in urine(pg) 153 13-929
Lead:CaNa2EDTA ratioe 0.47 0.05-2.90
'Blood lead level at the time of referral; to convert to
pmol/L multiply by 0.0483. hBlood lead level obtained on
the day ofthe challenge test. cSerum iron/total iron bind-
ing capacity; 58% were iron deficient (i.e., iron saturation
< 20%l. dTo convert to pmol/L, multiply by 0.0177. 'The
ratio of the micrograms of lead excreted in urine to the
milligrams ofCaNa2EDTA.
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test lacks specificity because only 25% of
negative challenge tests had an EP level
< 0.62 pmol/L (< 35 pg/dL).
A decreasing RATE (i.e., < 0 pg/dL/day)
was a fair predictor of a negative challenge
test. Eighty-six percent of challenge tests
with a decreasing RATE were negative.
This proportion did not markedly change
when RATE was stratified by the number
of days between the dates of the referral
blood lead level and the challenge test.
Among challenge tests done within 14 days
ofthe referral blood lead level, 81% with a
decreasing RATE were negative. Among
challenge tests done within 15-31 days of
the referral blood lead level, 88% with a
decreasing RATE were negative. However,
RATE at this cutoff lacks both sensitivity
and specificity in predicting the outcome
ofa challenge test (Table 4).
Ofthe two models forwhich multivariate
logistic regression was performed, the second
model (a medical provider who obtains a
repeat blood lead level 2-4 weeks after diag-
nosing a child with a moderately elevated
blood lead level) was the preferential scenario
for predicting the outcome ofa challenge test
when blood lead level at the time of chela-
tion, age, and RATE were entered into the
analysis. Table 5 lists the predicted probabili-
ty ofa challenge test according to this logistic
regression model by blood lead level, age, and
RATE. A predicted probability of 0.15 was
the threshold above which all true-positive
challenge tests were identified (100% sensi-
tivity), but 39% of true-negative challenge
tests were falsely classified as positive.
Discussion
The CDC recommends that the CaNa2-
EDTA challenge test be considered for
Table 3. Proportion of positive challenge tests
among all eligible challenge tests and among all
eligible challenge tests and challenge tests with
EP > 35 pg/dL, by strata of blood lead level.
Plinihin rh(allnnki Blood LiigiuI, LiIUidiIiyU
leada challenges with EP >35
(pg/dL) nb nc % nd n %
<25 9 0 0 6 0 0
25-29 29 0 0 16 0 0
30-34 61 10 16 37 10 27
35-39 40 1 1 28 30 1 1 37
40-44 19 8 42 16 7 44
45-49 9 4 44 8 4 50
50-54 7 5 71 7 5 71
Total 174 38 22 120 37 31
EP, erythrocyte protoporphyrin.
aBlood lead level on the day ofthe challenge test; to con-
vert to pmol/L multiply by 0.0483. bTotal number of chil-
dren with defined blood lead level; four children did not
have a blood lead level drawn. CTotal number of children
with defined blood lead level and positive challenge test.
dTotal number of children with defined blood lead level;
one child did not have a level drawn.
children who have blood lead levels of
1.21-2.12 pmol/L (25-44 pg/dL) to deter-
mine whether chelation is indicated (1).
However, some authors no longer recom-
mend the challenge test because of the
potential toxicity of CaNa2EDTA (11,12),
and the difficulty of obtaining complete
urine samples (12,13).
The assertion that CaNa2EDTA is
toxic arises from a study reporting that rats
receiving a single dose ofCaNa2EDTA had
an increase in brain lead level (14). In that
study, the dose of CaNa2EDTA associated
with increased brain lead levels was 150
mg/kg, but this phenomenon did not occur
at a dose of 75 mg/kg. Because an even
lower dose ofCaNa2EDTA, approximately
25 mg/kg, is recommended for the CaNa2-
EDTA challenge test (1), the results ofthat
study are not generalizable to children who
are candidates for the challenge test.
The assertion that it is difficult to
obtain complete urine samples is accurate.
However, this argues not for the abandon-
ment ofthis test, but rather that it be con-
ducted by personnel experienced in collect-
ing urine from young children. In 1997,
our center obtained complete collections
on 83% of children; the remaining chil-
dren sustained inconsequential urine losses
during the last 1-2 hr of the collection, a
period when CaNa2EDTA-induced lead
excretion is minimal.
At present, the blood lead level has
become the sole factor determining whether
a child undergoes chelation (1). Never-
theless, children with comparable blood
lead levels can have great differences in
body lead burden and thus different degrees
of lead diuresis in response to a chelating
agent. For example, only 3% of children
with an EP level < 0.62 imol/L (< 35
pg/dL) had a positive challenge test, in
comparison to 31% ofchildren who had an
EP level > 0.62 pmol/L (. 35 pg/dL)
despite comparable blood lead levels. This
reflects the heterogeneity that exists within
the population oflead-exposed children and
highlights the limitations of the blood lead
level in determining whom to chelate.
Table 4. Bivariate analysis of explanatory variables.
Authors have raised this issue and argued
that the challenge test is useful for identify-
ing whom to treat when blood lead levels
are moderately elevated (15,16). Our study
supports this contention. Among children
who have comparable blood lead levels, the
challenge test differentiates children who
will not have a significant CaNa2EDTA-
induced lead diuresis, and thus will not
benefit from chelation, from those who will
have a significant CaNa2EDTA-induced
lead diuresis, and thus are more likely to
benefit from chelation. Nevertheless, fur-
ther research is needed to define what con-
stitutes a significant level of chelation-
induced lead diuresis (13), preferably by
linking it to neurocognitive outcomes.
Our study found that readily obtain-
able tests can identify children likely to
have a negative challenge test. A low EP
level is excellent at identifying such chil-
dren; only 3% of challenge tests with an
EP level < 0.62 pmol/L (< 35 pg/dL) were
positive. This finding is comparable to the
4.8% reported by Markowitz et al. (15). A
decreasing blood lead level is a fair predic-
tor of a negative challenge test; 86% of
children whose blood lead level was
decreasing (i.e., RATE < 0 pg/dL/day) had
a negative challenge test. Additionally, cer-
tain blood lead levels were also predictive
of a negative challenge test; no challenge
tests were positive at blood lead levels
< 1.40 pmol/L (< 29 pg/dL). Previous
studies report that iron deficiency is associ-
ated with a lowered likelihood ofa positive
challenge test (10,15). Our study found
that iron saturation did not reliably distin-
guish the outcome of a challenge test; this
is not surprising because iron status was
previously noted to be weakly associated
with the outcome of the challenge test
(10). However, regarding bivariate analysis,
all the aforementioned variables misclassify
a large proportion of the true-positive or
true-negative challenge tests.
In logistic regression, we found that the
second model-a medical provider who
obtains a repeat blood lead level 2-4 weeks
after diagnosing a child with a moderately
Positive Negative
predictive predictive
Variable Cutoffa nb Sensitivityc Specificityd valuee valuef
Age 36 months 178 63 59 31 85
Iron saturationg 20% 168 46 59 24 79
Erythrocyte protoporphyrin 35 pg/dL 150 97 25 31 97
RATEh 0 pg/dL/day 174 53 79 42 86
aThe cutoff distinguishing positive from negative. Variables with values equal to or greater than the cutoff are defined as
positive tests; variables with values less than the cutoff are defined as negative tests. bSample size. cThe proportion of
positive challenge tests having a positive test. dThe proportion of negative challenge tests having a negative test. eThe
proportion of challenge tests having a positive testthat were positive. fThe proportion ofchallenge tests having a negative
test that were negative. 9Serum iron/total iron binding capacity. "Defined as the blood lead level on the day of the chal-
lenge test minus the blood lead level atthe time of referral, divided bythe number ofdays between the two lead levels.
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Table 5. Predicted probability of a positive chal-
lengetest by blood lead level, age, and RATE.
Lead Predicted
levela Age probabilityc
(pg/dl) (months) RATEb (%)
<25 <36 <0 0
<25 <36 .0 0
<25 .36 <0 2
<25 .36 .0 1
25-29 <36 <0 1
25-29 <36 .0 1
25-29 .36 <0 7
25-29 . 36 .0 3
30-34 <36 <0 4
30-34 <36 .0 2
30-34 . 36 <0 23
30-34 .36 .0 12
35-39 <36 <0 15
35-39 <36 .0 7
35-39 . 36 <0 54
35-39 .36 .0 35
40-44 <36 <0 41
40-44 <36 .0 24
40-44 .36 <0 82
40-44 .36 .0 68
45-49 <36 <0 73
45-49 <36 .0 55
45-49 .36 <0 95
45-49 .36 .0 89
50-54 <36 <0 91
50-54 < 36 .0 83
50-54 . 36 < 0 99
50-54 .36 .0 97
'To convertto pmol/L, multiply by 0.0483. bDefined as the
blood lead level on the day of the challenge test minus
the blood lead level atthe time of referral, divided by the
number of days between the two lead levels. "The pre-
dicted probability is equal to 11(1 + e-1 where z= -8.31 +
1.37(PB) + 1.90(age) - 0.80(RATE). PB is the blood lead
level in 5 pg/dL strata coded sequentially from 1 (< 25
pgldL) to 7 (50-54 pg/dL); age is coded 1 (< 36 months)
and 2 (> 36 months); and RATE is coded 1 (< 0 pg/dL/day)
and 2(.0 pg/dtLday).
elevated blood lead level [1.21-2.12
1mol/L (25-44 1pg/dL)]-resulted in the
best prediction when using blood lead level
at the time of chelation, age, and RATE.
This finding replicates, in part, the finding
ofa previous study that reported that blood
lead level, age, and EP level are predictive of
the outcome of a challenge test (15). We
recommend that a provider obtain a second
blood lead level 2-4 weeks after diagnosing
a child with a moderately elevated blood
lead level. The provider can subsequently
use Table 5 to determine the predicted
probability of a positive challenge test for
their patient and determine whether to
order such a test. According to our model,
predicted probabilities 2 15% would cor-
rectly classify 100% of true-positive chal-
lenge tests while misclassifying only 39% of
true-negative challenge tests. Alternatively,
providers who do not have access to the
challenge test may use Table 5 in deciding
whether to chelate empirically.
Providers should consider whether the
aforementioned findings apply to their
patients. The model may not be applicable
in instances where a repeat blood lead level
is obtained beyond 4 weeks ofthe diagnosis.
Additionally, because proficiency testing
programs for the assay of lead in urine do
not currently exist, providers should con-
duct the challenge test as we described in
"Methods" and be assured that their popula-
tion has comparable rates of positive chal-
lenge tests by strata of blood lead level.
Other studies have reported rates ofpositive
challenge tests comparable to those in our
study (15,17,18).
In summary, we recommend the chal-
lenge test for children 2 36 months of age
who have a blood lead level between 1.45
and 1.64 1smol/L (30-34 ,ug/dL) and for
children who have a blood lead level
1.69-2.12 gmol/L (35-44 pg/dL) regard-
less ofage.
Not all children with a blood lead level
of2.17-2.61 pmol/L (45-54 pg/dL) had a
positive challenge test. This suggests that
the challenge test, rather than chelation, be
considered for children whose blood lead
levels are in that range. Likewise, the data
also suggest that the blood lead level
threshold above which chelation be con-
ducted without a challenge test be defined
higher than 2.17 pmol/L (45 gg/dL), as
currently defined by the CDC (1).
However, we do not currently advocate
changing the threshold at which to chelate.
Rather, the assay oflead in urine should be
standardized by proficiency testing pro-
grams; subsequently, if our findings are
replicated at other centerswith asufficiently
large sample size, the change in these
thresholds should be considered.
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